RetinalGenix Technologies Inc. (RTGN) Financial Statements (2024 and earlier)

Company Profile

Business Address 1450 NORTH MCDOWELL BOULEVARD
PETALUMA, CA 94954
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,9137,470383,632272,555
Cash and cash equivalents1,9137,470383,632272,555
Total current assets:1,9137,470383,632272,555
Noncurrent Assets
Property, plant and equipment206231256282  
Total noncurrent assets:206231256282  
TOTAL ASSETS:2,1197,7012943,914272,555
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:697,073634,181475,480366,687350,657270,625
Interest and dividends payable5,5394,079
Accounts payable     339,579262,467
Accrued liabilities9,6798,7197,759 5,5394,079
Other undisclosed accounts payable and accrued liabilities687,394625,462467,721366,687  
Debt49,00049,00049,00048,00073,00073,000
Due to related parties537,118641,404257,084387,332
Total current liabilities:746,073683,1811,061,5981,056,091680,741730,957
Noncurrent Liabilities
Other undisclosed liabilities1,030,877825,7177,7596,799(5,539)(4,079)
Total liabilities:1,776,9501,508,8981,069,3571,062,890675,202726,878
Equity
Equity, attributable to parent(1,774,831)(1,501,197)(1,069,063)(1,058,976)(675,175)(724,323)
Common stock1,7831,7831,7831,7241,5191,484
Additional paid in capital8,104,4788,025,9697,947,4607,282,6405,162,1564,753,708
Accumulated deficit(9,881,092)(9,528,949)(9,018,306)(8,343,340)(5,838,850)(5,479,515)
Total equity:(1,774,831)(1,501,197)(1,069,063)(1,058,976)(675,175)(724,323)
TOTAL LIABILITIES AND EQUITY:2,1197,7012943,914272,555

Income Statement (P&L) (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Operating expenses(351,183)(509,683)(674,006)(2,503,230)(357,875)(373,739)
Other undisclosed operating loss   (160,595)   
Operating loss:(351,183)(509,683)(834,601)(2,503,230)(357,875)(449,411)
Interest and debt expense(960)(960)(960)(1,261)(1,460)(1,460)
Loss from continuing operations:(352,143)(510,643)(835,561)(2,504,491)(359,335)(450,871)
Loss before gain (loss) on sale of properties:(2,504,491)(359,335)(450,871)
Net loss:(352,143)(510,643)(835,561)(2,504,491)(359,335)(450,871)
Other undisclosed net income attributable to parent   160,615  75,672
Net loss available to common stockholders, diluted:(352,143)(510,643)(674,946)(2,504,491)(359,335)(375,199)

Comprehensive Income (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(352,143)(510,643)(835,561)(2,504,491)(359,335)(450,871)
Comprehensive loss, net of tax, attributable to parent:(352,143)(510,643)(835,561)(2,504,491)(359,335)(450,871)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: